Cargando…

CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy

HIV entry in the host cell requires the interaction with the CD4 membrane receptor, and depends on the activation of one or both co-receptors CCR5 and CXCR4. Former selective co-receptor antagonists, acting at early stages of infection, are able to impair the receptor functions, preventing the viral...

Descripción completa

Detalles Bibliográficos
Autores principales: Grande, Fedora, Occhiuzzi, Maria Antonietta, Rizzuti, Bruno, Ioele, Giuseppina, De Luca, Michele, Tucci, Paola, Svicher, Valentina, Aquaro, Stefano, Garofalo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384722/
https://www.ncbi.nlm.nih.gov/pubmed/30717348
http://dx.doi.org/10.3390/molecules24030550
_version_ 1783397044195426304
author Grande, Fedora
Occhiuzzi, Maria Antonietta
Rizzuti, Bruno
Ioele, Giuseppina
De Luca, Michele
Tucci, Paola
Svicher, Valentina
Aquaro, Stefano
Garofalo, Antonio
author_facet Grande, Fedora
Occhiuzzi, Maria Antonietta
Rizzuti, Bruno
Ioele, Giuseppina
De Luca, Michele
Tucci, Paola
Svicher, Valentina
Aquaro, Stefano
Garofalo, Antonio
author_sort Grande, Fedora
collection PubMed
description HIV entry in the host cell requires the interaction with the CD4 membrane receptor, and depends on the activation of one or both co-receptors CCR5 and CXCR4. Former selective co-receptor antagonists, acting at early stages of infection, are able to impair the receptor functions, preventing the viral spread toward AIDS. Due to the capability of HIV to develop resistance by switching from CCR5 to CXCR4, dual co-receptor antagonists could represent the next generation of AIDS prophylaxis drugs. We herein present a survey on relevant results published in the last few years on compounds acting simultaneously on both co-receptors, potentially useful as preventing agents or in combination with classical anti-retroviral drugs based therapy.
format Online
Article
Text
id pubmed-6384722
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63847222019-02-23 CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy Grande, Fedora Occhiuzzi, Maria Antonietta Rizzuti, Bruno Ioele, Giuseppina De Luca, Michele Tucci, Paola Svicher, Valentina Aquaro, Stefano Garofalo, Antonio Molecules Review HIV entry in the host cell requires the interaction with the CD4 membrane receptor, and depends on the activation of one or both co-receptors CCR5 and CXCR4. Former selective co-receptor antagonists, acting at early stages of infection, are able to impair the receptor functions, preventing the viral spread toward AIDS. Due to the capability of HIV to develop resistance by switching from CCR5 to CXCR4, dual co-receptor antagonists could represent the next generation of AIDS prophylaxis drugs. We herein present a survey on relevant results published in the last few years on compounds acting simultaneously on both co-receptors, potentially useful as preventing agents or in combination with classical anti-retroviral drugs based therapy. MDPI 2019-02-02 /pmc/articles/PMC6384722/ /pubmed/30717348 http://dx.doi.org/10.3390/molecules24030550 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Grande, Fedora
Occhiuzzi, Maria Antonietta
Rizzuti, Bruno
Ioele, Giuseppina
De Luca, Michele
Tucci, Paola
Svicher, Valentina
Aquaro, Stefano
Garofalo, Antonio
CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
title CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
title_full CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
title_fullStr CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
title_full_unstemmed CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
title_short CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
title_sort ccr5/cxcr4 dual antagonism for the improvement of hiv infection therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384722/
https://www.ncbi.nlm.nih.gov/pubmed/30717348
http://dx.doi.org/10.3390/molecules24030550
work_keys_str_mv AT grandefedora ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy
AT occhiuzzimariaantonietta ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy
AT rizzutibruno ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy
AT ioelegiuseppina ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy
AT delucamichele ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy
AT tuccipaola ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy
AT svichervalentina ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy
AT aquarostefano ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy
AT garofaloantonio ccr5cxcr4dualantagonismfortheimprovementofhivinfectiontherapy